Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Famitinib Malate Capsules (Old vs New Formulation)
NCT04400123Phase 1Completed
- Sponsor
- Hengrui
- Start
- May 2020
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of famitinib in colorectal cancer (CRC), renal cell carcinoma (RCC), gastrointestinal stromal tumor (GIST) and 1 more (2 arms), sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration at 192 hours and Area Under the Curve at 192 hours. Started May 2020; status: completed.
02
Drugs
famitinib
03
Conditions
colorectal cancer (CRC)renal cell carcinoma (RCC)gastrointestinal stromal tumor (GIST)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04400123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04400123.